Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Pitavastatin is a potent, synthetic statin drug belonging to the class of HMG-CoA reductase inhibitors, primarily utilized for managing dyslipidemia and reducing cardiovascular risk. Its molecular formula is C25H26FNO4, with a precise molecular weight of approximately 419.48 g/mol. The compound is uniquely identified by its CAS Registry Number, 173142-66-0. Structurally, Pitavastatin features a fluorophenyl group attached to a lactone ring system, which contributes to its high potency and specific metabolic profile compared to earlier generation statins like atorvastatin or simvastatin.
The primary therapeutic application of Pitavastatin involves lowering elevated levels of total cholesterol, low-density lipoprotein (LDL), and triglycerides while simultaneously raising high-density lipoprotein (HDL) cholesterol. It achieves this by competitively inhibiting the enzyme HMG-CoA reductase, a rate-limiting step in hepatic cholesterol biosynthesis. Beyond lipid regulation, clinical studies suggest Pitavastatin possesses favorable pleiotropic effects, including anti-inflammatory properties and improved endothelial function, which may further protect against atherosclerosis. A distinct advantage of Pitavastatin is its minimal metabolism via the cytochrome P450 3A4 pathway; instead, it undergoes limited glucuronidation and biliary excretion. This unique metabolic route significantly reduces the potential for drug-drug interactions, making it a preferred option for patients taking multiple medications, such as those on cyclosporine or certain antifungal agents.
Approved in various markets including Japan, South Korea, and more recently in the United States under brand names like Livalo, Pitavastatin is indicated for adults with hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. It is typically administered orally once daily, often without strict dietary restrictions regarding grapefruit juice, unlike some other statins. While generally well-tolerated, common side effects may include muscle pain, headache, or mild gastrointestinal disturbances. Rare but serious risks involve myopathy and rhabdomyolysis, necessitating periodic monitoring of liver enzymes and creatine kinase levels during therapy. As a next-generation statin, Pitavastatin represents a significant advancement in lipid-lowering therapy, offering an effective balance between efficacy, safety, and pharmacokinetic predictability for long-term cardiovascular disease prevention.